Race and Methotrexate Pharmacogenetics in Rheumatoid Arthritis

Abstract

To the Editor: Fisher and Cronstein are to be commended for their recent metaanalysis on methylenetetrahydrofolate reductase (MTHFR) polymorphisms and methotrexate (MTX) toxicity in rheumatoid arthritis (RA)1. Their work exposes the lack of sound pharmacogenetic data on MTX in RA and underscores that there is a long way to go before MTX pharmacogenetics is ready to guide clinical decision-making in RA. In the discussion, the authors note the paucity of data in the literature to determine whether the presence or absence of a single-nucleotide … Address correspondence to Dr. Ranganathan. E-mail: prangana{at}dom.wustl.edu